The apple (Malus ×domestica) cultivar Santana was shown to have a low allergenicity in a previously reported clinical trial. A protocol was developed to validate these results outside a clinical setting and to market the Santana as a hypoallergenic apple for large-scale consumption. This protocol was designed to ensure safe consumption of the Santana by consumers suffering from apple allergy. We tested the protocol in a pilot in 100 supermarket stores and evaluated in an internet-based survey with 295 respondents. Forty-one percent of the consumers with an apple allergy did not have an allergic reaction to the Santana. Only five percent of the allergic consumers that tried the Santana reported a strong allergic reaction. In concordance with this, the majority (78%) of the mild apple allergic consumers appreciated the Santana. The developed protocol is considered suitable for safe consumption of the Santana providing that information about the possibility of having an allergic reaction among consumers with a mild apple allergy is added to the label.
|Title of host publication||Proceedings of the II International Symposium on Human Health Effects of Fruits and Vegetables: FAVHEALTH 2007|
|Publication status||Published - 2009|